The stock has a 36-month beta value of 0.83. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for BPMC is 63.30M, and at present, short sellers hold a 8.79% of that float. On May 01, 2025, the average trading volume of BPMC was 1.06M shares.
BPMC) stock’s latest price update
Blueprint Medicines Corp (NASDAQ: BPMC) has experienced a rise in its stock price by 9.50 compared to its previous closing price of 89.50. However, the company has seen a gain of 13.84% in its stock price over the last five trading days. zacks.com reported 2025-05-01 that Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago.
BPMC’s Market Performance
Blueprint Medicines Corp (BPMC) has experienced a 13.84% rise in stock performance for the past week, with a 14.04% rise in the past month, and a -14.07% drop in the past quarter. The volatility ratio for the week is 3.25%, and the volatility levels for the past 30 days are at 5.21% for BPMC. The simple moving average for the last 20 days is 15.72% for BPMC’s stock, with a simple moving average of 4.26% for the last 200 days.
Analysts’ Opinion of BPMC
Many brokerage firms have already submitted their reports for BPMC stocks, with Morgan Stanley repeating the rating for BPMC by listing it as a “Equal-Weight.” The predicted price for BPMC in the upcoming period, according to Morgan Stanley is $100 based on the research report published on March 20, 2025 of the current year 2025.
Jefferies gave a rating of “Buy” to BPMC, setting the target price at $135 in the report published on March 17th of the current year.
BPMC Trading at 11.30% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.60% of loss for the given period.
Volatility was left at 5.21%, however, over the last 30 days, the volatility rate increased by 3.25%, as shares surge +10.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.30% upper at present.
During the last 5 trading sessions, BPMC rose by +15.07%, which changed the moving average for the period of 200-days by -17.13% in comparison to the 20-day moving average, which settled at $84.74. In addition, Blueprint Medicines Corp saw 12.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Haviland Kate, who sale 2,498 shares at the price of $86.65 back on Apr 01 ’25. After this action, Haviland Kate now owns 165,929 shares of Blueprint Medicines Corp, valued at $216,461 using the latest closing price.
KATHRYN D HAVILAND, the Officer of Blueprint Medicines Corp, proposed sale 2,498 shares at $88.51 during a trade that took place back on Apr 01 ’25, which means that KATHRYN D HAVILAND is holding shares at $221,098 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.42 for the present operating margin
- 0.94 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.13. The total capital return value is set at -0.23. Equity return is now at value -31.26, with -6.02 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.61 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at 1.57. The interest coverage ratio of the stock is -3.08.
Currently, EBITDA for the company is 19.23 million with net debt to EBITDA at -2.24. When we switch over and look at the enterprise to sales, we see a ratio of 13.13. The receivables turnover for the company is 6.56for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.85.
Conclusion
To sum up, Blueprint Medicines Corp (BPMC) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
